RHÖN-KLINIKUM Aktiengesellschaft
ISIN: DE0007042301
WKN: 704230
27 March 2025 09:59AM

EQS-News: RHÖN-KLINIKUM AG once again reports a successful financial year – CEO Prof. Kaltenbach leaves the Board of Management as planned

RHÖN-KLINIKUM Aktiengesellschaft · ISIN: DE0007042301 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 2107452

EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Annual Report/Annual Results
RHÖN-KLINIKUM AG once again reports a successful financial year – CEO Prof. Kaltenbach leaves the Board of Management as planned

27.03.2025 / 09:59 CET/CEST
The issuer is solely responsible for the content of this announcement.


 


Corporate News

Bad Neustadt a. d. Saale | 27 March 2025

 

 

RHÖN-KLINIKUM AG once again reports a successful financial year – CEO Prof. Kaltenbach leaves the Board of Management as planned


RHÖN-KLINIKUM AG has met its financial targets as per forecast. Revenue increased by 131.6 million euros to reach 1,595.6 million euros (previous year: 1,464.0 million euros). The increase was driven by growth in patient numbers and related services. A total of 912,965 patients (previous year: 881,775) were treated on an inpatient and outpatient basis in the Group’s hospitals and medical care centres – an increase of 3.5 per cent. Consolidated profit improved by 5.0 million euros to 45.2 million euros (previous year: 40.2 million euros).  Earnings before interest, taxes, depreciation and amortisation (EBITDA) recorded at 110.8 million euros (previous year: 105.9 million euros). Materials and consumables used increased as a result of higher purchasing prices to 535.5 million euros (previous year: 488.5 million euros).

“RHÖN-KLINIKUM AG can once again look back on a successful financial year in 2024 with a satisfactory performance. Our forecasted performance indicators were reached, with revenues and earnings going up for the third year in a row. This is more than remarkable given the trend in the sector, which for three years has been going in exactly the opposite direction”, said Dr. Stefan Stranz, member of the Board of Management of RHÖN-KLINIKUM AG.

The Company has been very quick to adapt to the tremendous challenges faced by the sector whilst also anticipating how to leverage its portfolio, structures and processes to prepare for the new requirements introduced by the reform. This in turn enables stable earnings to be generated.

Acting sustainably is a non-negotiable for RHÖN-KLINIKUM AG. To achieve this goal, the Company has set sustainability targets. In the environmental area, RHÖN is striving to significantly reduce the CO2 emissions of its healthcare facilities (Scope 1 and 2). We are also aiming to lower waste volumes in proportion to patient numbers. Currently, a transition plan for climate change mitigation is being prepared and, in this context, the sustainability strategy adapted. The strategy is to complete and implement the plan  within the next three years. We report on this in our Sustainability Report, in which we adopted ESRS Standards following the European CSRD Directive for the first time.

 

Change on the Board of Management

Given the Group’s ongoing integration into the Asklepios Group, the Supervisory Board of RHÖN-KLINIKUM AG, in close consultation with Prof. Dr. Tobias Kaltenbach, chairman of the Board of Management of RHÖN-KLINIKUM AG, has taken a further strategic move by reducing the size of the Board of Management of the Company to two individuals. In this context, Prof. Dr. Kaltenbach (64) will leave the Board of Management with effect from 31 March 2025. As of 1 April 2025 the Board of Management of the Company will thus consist of Dr. Stefan Stranz and Dr. Gunther K. Weiß. Prof. Dr. Kaltenbach had been serving as chairman of the Board of Management since 2023.

“On behalf of the Supervisory Board, I wish to express my sincere thanks to Prof. Dr. Tobias Kaltenbach for his tremendous service. He has not only ushered in important steps in the strategic partnership of RHÖN and Asklepios, but was also decisive in brokering the White Paper Plus agreement on further cooperation with the Federal State of Hesse at Universitätsklinikum Gießen und Marburg (UKGM). It was also under his leadership that RHÖN-KLINIKUM AG succeeded in continuously improving its financial results. Together with the entire Supervisory Board, I wish Prof. Dr. Tobias Kaltenbach every success both personally and in his future career,” said Dr. Jan Liersch, chairman of the Supervisory Board of RHÖN-KLINIKUM AG.

Prof. Dr. Kaltenbach added: “The past years have been intense, bringing tremendous challenges which we have overcome as we worked together with the Supervisory Board on the basis of mutual trust. That is something I am very grateful for. I also wish to extend my special thanks to our more than 18,000 employees for the decisive contributions they have made to the Company’s overall success thanks to their hard work, loyalty and commitment. Each and every one of them plays a key role in this outstanding team.”


Outlook for 2025

For the coming financial year, we expect revenue of € 1.7 billion within a range of plus or minus 5%. For earnings before interest, tax and depreciation/amortisation (EBITDA), we expect a level of between € 110 million and € 125 million. In addition to the financial numbers, we also take account of the non-financial performance indicators of number of cases and cost weights in the management of the Company and expect these to show a moderate increase over the previous year.

This forecast reflects the heightened regulatory interference by the German legislator and the political implementation of the necessary hospital reform.

We note that our outlook is subject to considerable uncertainties in connection with the numerous global crises resulting among other things in higher prices and supply chain issues, as well as any further regulatory measures impacting our remuneration structure for medical services in 2025.

 

 

RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 912,965 patients are treated at our five sites of Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs over 18,700 persons. The innovative RHÖN Campus approach for cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with Asklepios are important elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA. www.rhoen-klinikum-ag.com


Annual Report 2024
 

 


Contact:
RHÖN-KLINIKUM AG |Head of Corporate Finance, Treasury, Investor Relations and Sustainability
Julian Schmitt 
T. +49 9771 65-12250 | julian.schmitt@rhoen-klinikum-ag.com


RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale



27.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: RHÖN-KLINIKUM Aktiengesellschaft
Salzburger Leite 1
97616 Bad Neustadt a. d. Saale
Germany
Phone: +49 (0)9771 - 65-0
Fax: +49 (0)9771 - 97 467
E-mail: rka@rhoen-klinikum-ag.com
Internet: www.rhoen-klinikum-ag.com
ISIN: DE0007042301
WKN: 704230
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
EQS News ID: 2107452

 
End of News EQS News Service

2107452  27.03.2025 CET/CEST

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2019 2020 2021 2022 2023 2024 2025e
Sales1 1.303,90 1.360,16 1.402,01 1.446,09 1.463,98 1.595,62 1.700,00
EBITDA1,2 125,33 80,23 101,16 105,65 105,88 110,77 119,00
EBITDA-Margin3 9,61 5,90 7,22 7,31 7,23 6,94 7,00
EBIT1,4 56,80 10,60 30,52 36,11 40,40 48,15 59,00
EBIT-Margin5 4,36 0,78 2,18 2,50 2,76 3,02 3,47
Net Profit (Loss)1 44,48 2,46 30,23 26,94 40,17 45,21 48,00
Net-Margin6 3,41 0,18 2,16 1,86 2,74 2,83 2,82
Cashflow1,7 47,30 113,30 97,50 41,30 109,00 127,60 110,00
Earnings per share8 0,65 0,02 0,42 0,38 0,58 0,65 0,72
Dividend per share8 0,00 0,00 0,00 0,15 0,00 0,10 0,10
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: KPMG

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Rhön-Klinikum
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
704230 DE0007042301 AG 837,03 Mio € 19.06.1991 Halten 9F2G86FM+GX
* * *
PE 2026e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
15,82 27,27 0,58 22,65 0,65 6,56 0,52
Dividends
Dividend '2023
in €
Dividend '2024
in €
Dividend '2025e
in €
Div.-Yield '2025e
in %
0,00 0,10 0,10 0,80%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
03.06.2025 08.05.2025 07.08.2025 06.11.2025 27.03.2025
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+0,81%
12,50 €
ATH 32,12 €
+5,41% -0,77% -10,07% -4,58% +400,00%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2025          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2025 by Gereon Kruse #BGFL